Compare IMUX & RCMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMUX | RCMT |
|---|---|---|
| Founded | 2016 | 1971 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.2M | 198.3M |
| IPO Year | 2013 | 1997 |
| Metric | IMUX | RCMT |
|---|---|---|
| Price | $14.54 | $28.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $36.00 | $36.00 |
| AVG Volume (30 Days) | ★ 134.9K | 31.4K |
| Earning Date | 05-14-2026 | 04-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | 27.38 |
| EPS | N/A | ★ 0.52 |
| Revenue | N/A | ★ $186,737,000.00 |
| Revenue This Year | N/A | $11.89 |
| Revenue Next Year | N/A | $12.46 |
| P/E Ratio | ★ N/A | $55.88 |
| Revenue Growth | N/A | ★ 5.83 |
| 52 Week Low | $0.51 | $17.26 |
| 52 Week High | $15.84 | $32.50 |
| Indicator | IMUX | RCMT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions, including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, and Europe.